Medical Management of Thyroid Cancer

  • Ajay Sood
  • S. Sethu Reddy
Part of the Current Clinical Oncology book series (CCO)


Thyroid cancer, the most common endocrine malignancy, accounts for 1.1% of all the newly diagnosed malignancies in the United States (1). It occurs three times more commonly in women. Its annual incidence has increased over the last few decades, possibly in part owing to improved diagnosis and cancer registration (2). However, the mortality rates owing to thyroid cancer have decreased by 20% between the years 1973 and 1996, because of early diagnosis, and better surveillance and treatment.


Thyroid Cancer Bone Metastasis Thyroid Carcinoma Papillary Thyroid Carcinoma Total Thyroidectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996, CA 1996; 46:5–27.Google Scholar
  2. 2.
    Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1973–1997. Bethesda, MD: National Cancer Institute; 2000.Google Scholar
  3. 3.
    Oertel J, Oertel Y. Classification of thyroid malignancies. In: Wartofsky, L, ed. Thyroid Cancer: A Comprehensive Guide to Clinical Management. Totowa, NJ: Humana Press; 2000:117–119.Google Scholar
  4. 4.
    Hundahl SA, Fleming ID, Freanger A, Merck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998; 83:2638–2648.PubMedCrossRefGoogle Scholar
  5. 5.
    Pittas AG, Adler M, Fazzari M, et al. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000; 10:261–268.PubMedGoogle Scholar
  6. 6.
    Bernier MO, Leenhardt L, Hoang C. et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001; 86:1568–1573.PubMedCrossRefGoogle Scholar
  7. 7.
    Marcocci D, Pacini F, Elisei R, et al. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 1989; 106:960–966.PubMedGoogle Scholar
  8. 8.
    Proye CAG, Dromen DHR, Carnaille BM, et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 1922; 16:640–646.CrossRefGoogle Scholar
  9. 9.
    Salvarti M, Frati A, Rocchi G, et al. Single brain metastasis from thyroid cancer: report of twelve cases and review of literature. J Neurooncol 2001; 51:33–40.CrossRefGoogle Scholar
  10. 10.
    Mohan V, Bhushan B, Sahai SB, Arora MM. Osteosclerotric metastasis from thyroid carcinoma. Australs Radiol 1987; 31:204–207.CrossRefGoogle Scholar
  11. 11.
    Tickoo SK, Pittas AG, Adler M et al. Bone metastases from thyroid carcinoma: a histopathologic study with clinical correlates. Arch Pathol Lab Med 2000; 124:1440–1447.PubMedGoogle Scholar
  12. 12.
    Lawrence E, Lord ST, Leon Y, et al. Tall cell pa+prillary thyroid carcinoma metastatic to femur: evidence for thyroid hormone synthesis within the femur. Am.J. Med. Sci 2001; 322:103–108.PubMedCrossRefGoogle Scholar
  13. 13.
    Chen LH, Chen WJ, Niu CC, Shih CH. Anterior reconstructive spinal surgery with Zielke Instrumentation for metastatic malignancies of the spine. Arch Orthop Trauma Surg 2000; 120:27–31.PubMedGoogle Scholar
  14. 14.
    Fornasier VL, Horne JG. Metastases to the vertebral column. Cancer 1975; 36:590–594.PubMedCrossRefGoogle Scholar
  15. 15.
    Ganly I, Crowther, J. Insular carcinoma of thyroid precenting as cervical cord compression. J Laryngol Otol 2000; 114:808–810.PubMedCrossRefGoogle Scholar
  16. 16.
    Shortliffe EH, Crapo LM. Thyroid carcinoma with spinal cord compression. JAMA 1982; 247:1565–1566.PubMedCrossRefGoogle Scholar
  17. 17.
    Masmiquel L, Simo R, Galofre P, Mesa J. Differentiated thyroid carcinoma as a cause of cervical spinal injury. J. Cancer Res Clin Oncol 1995; 121:189–191.PubMedCrossRefGoogle Scholar
  18. 18.
    Goldstein SI, Kaufman D, Abati AD. Metastatic thyroid carcinoma presenting as distal spinal cord compression. Ann Otol Rhinol Laryngol 1988; 97:393–396.PubMedGoogle Scholar
  19. 19.
    Koranda P, Ryznar V, Dockal M, Chrolok J, Houdek M. Papillary adenocarcinoma of the thyroid gland metastasizing in to the epidural space of the upper thoracic spine, without vertebral Involvement-case report. Acta Univ Palacki Olomuc Fac Med 1993; 135:31–32.PubMedGoogle Scholar
  20. 20.
    Roberts L Jr, Drayer BP, Apple JS, Martinez S. An unusual presentation of thyroid papillary Carcinoma: enlargement of a cervical intervertebral foramen. Comput Radiol 1986; 10:45–49.PubMedCrossRefGoogle Scholar
  21. 21.
    Hashizume Y, Hirano A. Intramedullary spinal cord metastasis. Pathologic findings in five autopsy cases. Acta Neuropathol (Ber) 1983; 61:214–218.CrossRefGoogle Scholar
  22. 22.
    Zeidman A, Sender BZ, Badear J, Fradim Z. Follicular carcinoma of the thyroid presenting as back pain and paravertebral mass. Israel Med Assoc J Imaj 2000; 2:720–721.Google Scholar
  23. 23.
    Kashab M, Boker DK. Indication for surgery of spinal metastases within the cervical region. Neurosurg Rev 1988; 11:95–97.PubMedCrossRefGoogle Scholar
  24. 24.
    Oertel YC. Fine-needle aspiration and the diagnosis of thyroid cancer. Endocrinol Metab Clin North Am 1996; 25:69–91.PubMedCrossRefGoogle Scholar
  25. 25.
    Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PPB. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clinical Endocrinol Metab 1997; 82:3553–3562.CrossRefGoogle Scholar
  26. 26.
    Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Chin Endocrinol Metab 2001; 86:1447–1463.CrossRefGoogle Scholar
  27. 27.
    Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinoma: a retrospective review of 1599 patients. Clin Endocrinol Metab 1992; 75:714–720.CrossRefGoogle Scholar
  28. 28.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am Med 1994; 97:418–428.CrossRefGoogle Scholar
  29. 29.
    Casara D, Rubello D, Saladin, G, Gallo V, Masarott G, Busnardo B. Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors in 214 patients. Tumori 1991: 77:432–436.PubMedGoogle Scholar
  30. 30.
    Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984; 57:323–327.PubMedCrossRefGoogle Scholar
  31. 31.
    Mazzaferri EL. NCCN thyroid carcinoma practice guidelines. National Comprehensive Cancer Network Proceedings 1999, Oncology 1999; 13: 391–442.Google Scholar
  32. 32.
    Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland-The Gustave-Roussy Institute Experience. Cancer 1998; 83:553–559.PubMedCrossRefGoogle Scholar
  33. 33.
    Maxon HR, Englaro EE, Thomas SR, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: outcome and validation in 85 patients. Nucl Med 1992; 33:1132–1136.Google Scholar
  34. 34.
    Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996; 20:88–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinal Metab 1998; 83:4195–4199.CrossRefGoogle Scholar
  36. 36.
    Hunt WB, Crispell KR, McKee J. Functioning metastatic carcinoma of the thyroid producting clinical hyperthyroidism. Am Med 1960; 28:995–1001.CrossRefGoogle Scholar
  37. 37.
    Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997; 7:265–271.PubMedGoogle Scholar
  38. 38.
    Doi SA, Woodhouse NJ. Ablation of the thyroid remant and 131I dose in differentiated thyroid cancer. Clin Endocrinal (Orf) 2000; 52 765–773.CrossRefGoogle Scholar
  39. 39.
    Muratet JP, Dave, A, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma. J Nucl Med 1998; 39:1546–1550.PubMedGoogle Scholar
  40. 40.
    Haugen BR, Pacini F, Reiners C, et al. A comparision of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877–3885.PubMedCrossRefGoogle Scholar
  41. 41.
    McDougall IR, Weigel RJ. Recombinant human thyrotropin in the management of thyroid cancer. Curr Opinion Oncol 2001; 13:39–43.CrossRefGoogle Scholar
  42. 42.
    Luster M, Reinhardt W, Korber C, et al. The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production. J Endocrinol Invest 2000; 23:473–475.PubMedGoogle Scholar
  43. 43.
    Maxon HR III, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endo Metab Clinc N. Amer 1990; 19:685–718.Google Scholar
  44. 44.
    Laguna R, Silva F, Vazquez-Selles J, Orduna E, Flores C. Vertebral hemangioma mimicking a metastatic bone lesion in well-differentiated thyroid carcinoma. Clin Nucl Med 2000; 25:611–613.PubMedCrossRefGoogle Scholar
  45. 45.
    Barzel US, Chun KJ. Artifact of I-131 whole body scan with thoracic vertebral uptake in a patient with papillary thyroid carcinoma. Clin Nucl Med 1997; 22:855.PubMedCrossRefGoogle Scholar
  46. 46.
    Schlumberger M, Mancusi F, Baudin E, Pacini F. 131-I therapy for elevated thyroglobulin levels. Thyroid 1997; 7:27–276.Google Scholar
  47. 47.
    Fatourechi V, Hay ID, Mullan BP, et al. Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 2000; 10:573–577.PubMedGoogle Scholar
  48. 48.
    Shiga T, Tsukamoto E, Nakuda K, et al. Comparison of (18) FFDG, (131) I-Na, and (201) T1 in diagnosis of recurrent or metastatic thyroid carcinoma. J. Nucl Med 2001; 42:414–419.PubMedGoogle Scholar
  49. 49.
    Nishiyama Y, Yamamoto Y, Ono Y, et al. Comparison of 99 Tcmtetrofosmin with 201 T1 and 131I in the detection of differentiated thyroid cancer metastases. Nucl Med Commum 2000: 21:917–923.CrossRefGoogle Scholar
  50. 50.
    Rubello D, Mazzarotto R, Casara D. The role of technetium-99 m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 2000; 27:431–440.PubMedCrossRefGoogle Scholar
  51. 51.
    Ng DC, Sundoam FX, Sin AE. 99m Tc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma. J. Nucl Med 2000; 41:631–635.PubMedGoogle Scholar
  52. 52.
    Bushnell DL, Boles MA, Kaufman GE, Wades MA, Barnes WE. Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J. Nucl Med 1992; 33:2214–2221.PubMedGoogle Scholar
  53. 53.
    Lakshmanan M, Schaffer A, Robbins J, Reynolds J, Norton J. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer. Clin Nucl Med 1988; 13:866–868.PubMedCrossRefGoogle Scholar
  54. 54.
    Koogn SS, Reynolds JC. Movius EG, et al. Lithium as a potential adjuvant to the 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999; 84:912–916.CrossRefGoogle Scholar
  55. 55.
    Brierley JD, Tsang RW. External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clin N Am 1996; 25:141–157.CrossRefGoogle Scholar
  56. 56.
    Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB. The effects of surgery, radioiodine, and ezxternal radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998; 82:375–388.PubMedCrossRefGoogle Scholar
  57. 57.
    Lessin LS, Min M. Chemotherapy of differentiated (papillary or follicular) thyroid carcinoma. In: Wartofsky L, ed. Thyroid Cancer. A Comprehensive Guide to Clinical Management. Totowa, NJ: Humana Press; 2000:221–223.Google Scholar
  58. 58.
    Pujol P, Daure JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinal Metal 1996; 81:4318–4323.CrossRefGoogle Scholar
  59. 59.
    Sijanovic S, Karner I. Bone loss in preminopausal women on longterm suppressive therapy with thyroid hormone. Medscape Womens Health 2001; 6:3.PubMedGoogle Scholar
  60. 60.
    Rosen HN, Moses AC, Garber J, et al. Randomized trial of pamidronate in patients with thyroid cancer: bone density is not reduced by suppressive does of thyroxine, but is increased by cyclic intravenous pamidronate. J Clin Endocrinol Metab 1998: 83:2324–2330.PubMedCrossRefGoogle Scholar
  61. 61.
    Frusciante V, Carnevale V, Scillitani A, et al. Global skeletal uptake of technicium-99m methylene disphosphonate in female patients receiving suppressive doses of L-thyroxine and differentiated thyroid cancer. Eur J Nucl Med 1998; 25:139–143.PubMedCrossRefGoogle Scholar
  62. 62.
    Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 2001; 358:861–865.PubMedCrossRefGoogle Scholar
  63. 63.
    Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8:737–744.PubMedGoogle Scholar
  64. 64.
    Carilleux AF, Baudin E, Travagli JP, Richard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85:175–178.Google Scholar
  65. 65.
    Grunwald F, Menzel C, Fimmes R, Zamoro PO, Briersack HJ. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med 1996; 37:1962–1964.PubMedGoogle Scholar
  66. 66.
    Wartofsky L. Using baseline and recombinant human TSH-stimulated Tg measurements to manage thyroid cancer with diagnostic 131I scanning. J Clin Endocrinol Metab 2002; 87:1486–1489.PubMedCrossRefGoogle Scholar
  67. 67.
    Robbins RJ, Chon JT, Fleischer M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient by itself, to monitor for residula thyroid carcinoma? J Clin Endocrinol Metab 2002; 87:3242–3247.PubMedCrossRefGoogle Scholar
  68. 68.
    Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin antoantibodies: Prevalence, influence on serum thyroglobulin measurements, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Erndocrinol metal 1998; 83:1121–1127.CrossRefGoogle Scholar
  69. 69.
    Stabin MG. Radiation dose to the upper spine from therapeutic administrations of iodine-131-sodium iodide. J Nucl Med 1993; 34:695–696.PubMedGoogle Scholar
  70. 70.
    VanTol KM, Hew JM, Jager PL, Verney A, Dullaart RP, Links TP. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin Endocrinal (Oxf) 2000; 52:653–659.CrossRefGoogle Scholar
  71. 71.
    Smit JW, Vielvoye GJ, Goslings BM. Embolization for vertebral metastases of follicular thyroid carconoma. J Clin Endocrinol Metab 2000; 85:989–994.PubMedCrossRefGoogle Scholar
  72. 72.
    Shirakusa T, Motonaga R, Yoshimine K, et al. Anterior rib strut grafting for the treatment of malignant lesions in the thoracic spine. Arch Orthop Trauma Surg 1989; 108:268–272.PubMedCrossRefGoogle Scholar
  73. 73.
    Gimm O, Sutter T, Dralle H. Diagnosis and therapy of sporadic and familial medullary thyroid carcinoma. J Cancer Res Clin Oncol 2001: 127:156–165.PubMedCrossRefGoogle Scholar
  74. 74.
    Lips CF, Hoppener JW, Thijssen JH. Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem 2001; 38:168–179.PubMedCrossRefGoogle Scholar
  75. 75.
    Ain KB. Anaplastic thyroid carcinoma: behavior biology, and therapeutic approaches. Thyroid 1998; 8:715–726.PubMedGoogle Scholar
  76. 76.
    Behr TM, Wulst E, Radetzky S, et al. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunotheraapy: doxorubicin potentiates the therapeutic efficacy of radiolabelled antibodies in a radioresistant tumor type. Cancer Res 1997; 57:5309A–5319A.Google Scholar
  77. 77.
    DeGroot LJ, Zhang R. Gene therapy for thyroid cancer; where do we stand? J Clin Endocrinol Metab 2001; 86:2923–2928.PubMedCrossRefGoogle Scholar
  78. 78.
    Spitzweg C, Harrington KJ, Pinke LA. Vile RG, Morris JC. The sodium iodide symporter and its potential role in cancer therapy. J Clin Endocrinol Metab 2001; 86:3327–3335.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Ajay Sood
    • 1
  • S. Sethu Reddy
    • 2
  1. 1.Department of Internal MedicineThe Cleveland Clinic FoundationCleveland
  2. 2.Department of Endocrinology, Diabetes and MetabolismThe Cleveland Clinic FoundationCleveland

Personalised recommendations